GT Biopharma, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
GT Biopharma issued a pre-funded common stock purchase warrant to PDPC Advisors Inc. on April 1, 2026, for 400,000 warrant shares with a nominal exercise price of $0.001 per share. The aggregate exercise price was pre-funded upfront by the holder. The warrant is exercisable immediately and indefinitely, with cashless exercise rights and standard anti-dilution protections including adjustments for stock splits, dividends, and fundamental transactions.
Why this rating
Warrant issuance is routine equity financing. At $8.6M market cap, 400K shares (~typical for small biotech) represent material but not transformational dilution if fully exercised. Pre-funded structure means cash received upfront, reducing immediate financing pressure. No adverse terms disclosed.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.